NeuroPace. has been granted a patent for an implantable medical device that assesses the effectiveness of a patient’s drug regimen by analyzing brain activity. The device delivers electrical stimulation, detects epileptiform events, and adjusts stimulation parameters to optimize therapy based on physiological feedback. GlobalData’s report on NeuroPace gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on NeuroPace, Electrical stimulation wearables was a key innovation area identified from patents. NeuroPace's grant share as of July 2024 was 79%. Grant share is based on the ratio of number of grants to total number of patents.
Implantable device assessing drug regimen effectiveness via neurostimulation
The patent US12029581B2 describes an innovative implantable medical device designed for use in a patient's brain to evaluate the effectiveness of their current drug regimen. The device features one or more electrodes implanted in or on the brain's surface, coupled with a neurostimulator. This neurostimulator is capable of delivering electrical stimulation therapy while continuously monitoring the brain's electrical activity. It can detect epileptiform events and evoked responses, calculate relevant metrics, and log data over time. The device assesses whether the existing drug regimen is effective by comparing tracked metrics against baseline metrics, which may be derived from pre-treatment electrographic signals or preset values. If the drug regimen is deemed ineffective, the device can adjust stimulation parameters accordingly.
Additionally, the device can generate signals to indicate necessary changes to the drug regimen, which may include modifications to the type, dosage, or delivery method of the drug. It can also implement these changes directly through an implantable drug-eluting lead or adjust stimulation parameters via a stimulation module. The logged information includes counts and durations of epileptiform events, measures of evoked responses, and power measures of specific frequency bands in the electrographic signal. The device is designed to operate over a minimum time period of 24 hours, ensuring comprehensive assessment and adjustment capabilities for optimizing patient treatment.
To know more about GlobalData’s detailed insights on NeuroPace, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
